New combo tackles rare lung cancer

NCT ID NCT04224337

Completed Disease control Sponsor: Seoul National University Hospital Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial tested a combination of the immunotherapy drug durvalumab with two chemotherapy drugs (doxorubicin and ifosfamide) in 16 people with a rare and aggressive type of lung cancer called pulmonary sarcomatoid carcinoma. The goal was to see if the combination could shrink tumors and improve survival. The study is complete, and results will help determine if this approach is worth further study.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: durvalumab (immunotherapy) plus doxorubicin and ifosfamide (chemotherapy)
What this could lead to: If successful, this combination could offer a new treatment option for a rare and aggressive lung cancer, potentially improving response rates and survival.
What could go wrong: This is a small, early-phase trial with only 16 participants, so results may not apply broadly. The combination also carries risks from chemotherapy side effects and immune-related reactions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CARCINOMA, NON-SMALL-CELL LUNG are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

lung sarcomatoid carcinoma non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CARCINOMA, NON-SMALL-CELL LUNG

Contacts and locations

Show contact details

Locations

Seoul National University Hospital

Seoul, Seoul, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.